Regulatory Inspection (Form 483 Issued)
Alkem Laboratories Receives US FDA Form 483 with 7 Observations at Daman Facility
NSE
alkem
BSE
539523
Alkem Laboratories has received US FDA Form 483 with seven observations following an inspection of its Daman manufacturing facility. The company will respond within the stipulated timeline
PRICE-SENSITIVE TRIGGER
Event: US FDA Inspection Outcome
Type: Regulatory Inspection (Form 483 Issued)
Impact: Negative (Mild to Moderate)
Immediate Effect: Signals compliance gaps flagged by US FDA; potential regulatory overhang until resolution
What Happened ?
The US Food and Drug Administration (FDA) conducted an inspection at Alkem’s manufacturing facility in Amaliya, Daman between:
- April 20, 2026 – May 1, 2026
Post inspection:
- The company received Form 483 with 7 observations
- These observations relate to procedural or compliance deficiencies
- Company has committed to addressing them within the given timeline
key highlights
Inspection Overview:
- Facility: Amaliya, Daman
- Inspection period: April 20 – May 1, 2026
- Conducted by: US FDA
Form 483 Observations:
- Total observations: 7
- Indicates gaps in:
- Manufacturing practices
- Documentation / compliance systems
- Not a final regulatory action (like Warning Letter)
Next Steps by Company:
- Will submit response to FDA
- Address observations within stipulated timeframe
- Aim to maintain compliance status
Note:
Form 483 is not a ban or import alert, but unresolved issues can escalate
Risk Analysis
Key Risks
- Possibility of escalation to:
- Warning Letter
- Import Alert (worst case)
- Impact on US exports if issues persist
- Compliance cost increase
- Reputation risk in regulated markets
Worst Case Scenario
- Failure to resolve observations could lead to USFDA warning letter or import restrictions, impacting revenue from US markets
Risk Level: Medium
Company Commentary
- US FDA inspection completed
- Received Form 483 with 7 observations
- Company will address all observations within stipulated time
Official Exchange Filing: Alkem Laboratories Limited